WO2017029261A1

WO2017029261A1 - Combination drug comprising finerenone and an nep-inhibitor (sacubitril)

Info

Publication number: WO2017029261A1
Application number: PCT/EP2016/069336
Authority: WO
Inventors: Peter Kolkhof; Peter Sandner; Christina NOWAK
Original assignee: Bayer Pharma Aktiengesellschaft
Priority date: 2015-08-19
Filing date: 2016-08-15
Publication date: 2017-02-23

Abstract

The invention relates to the use of the mineralocorticoid receptor antagonist finerenone combined with an inhibitor of the neutral endopeptidase (NEP), for treating and/or preventing cardiovascular diseases, renal diseases, lung disorders, and for treating and/or prophylaxis of fibrotic diseases.

Description

COMBINATION PREPARATION COMPRISING FERNERENONE AND A NEP INHIBITOR (SACUBITRIL)

The present invention relates to the use of the mineralocorticoid receptor antagonist Finerenone in combination with an inhibitor of neutral endopeptidase (NEP), for the treatment and / or prophylaxis of cardiovascular diseases, renal diseases, lung diseases, 5 and for the treatment and / or Prophylaxis of fibrotic diseases.

The entire Κο βΓ & ηΙίΙϊοη of humans and animals is controlled and maintained by regulating cycles. Components of these physiological regulatory circuits are again cascade systems of endogenous hormones, enzymes and receptors. These control circuits are interconnected and centrally controlled. Pathophysiological changes within

10 of the body, but also external influences such. Climate, stress, nutritional components including medications have a direct influence on these regulatory circuits. This diminished or excessive activities of individual components of these cascades and control systems can be compensated by countermeasure by means of so-called "feed-back" or also feed-forward mechanisms. A short-term

15 counter-control, e.g. by a compensatory release of a certain endogenous hormone is thus vital for the maintenance of Κό ετίυϊΐΜϊοη in emergency situations (for example, in injuries). However, a permanent compensatory counterregulation can have fatal consequences for the entire organism in the long term.

One of these essential control systems is the so-called renin-angiotensin-aldosterone system

20 (RAAS). It is a central cascade system of hormones and enzymes affecting the salt and water

Water balance and thus control the blood pressure of the body. Due to lack of salt and fluid or blood pressure drops, the hormone renin is formed and released in special kidney cells. Renin cleaves the liver-formed angiotensinogen into angiotensin I while the angiotensin-converting enzyme (ACE) converts angiotensin I into angiotensin II. Angiotensin II has potent 25 vasoconstrictive and thus hypertensive effects and stimulates the formation of the steroid hormone aldosterone in the adrenal cortex. Aldosterone promotes the recovery of sodium from the urine into the blood, increasing blood volume.

The specific effects of angiotensin II are mediated via corresponding extracellular receptors (angiotensin receptor, AT-R), which expresses on target cells of the cardiovascular system

30 will be. In contrast, the specific effects of aldosterone are mediated via an intracellular receptor, the aldosterone or mineralocorticoid receptor (MR). In addition to their central importance in the regulation of salt, water and blood pressure, both angiotensin 11 and aldosterone have direct pro-inflammatory and fibrotic properties. Both hormones play an important role, in particular during remodeling ('remodeling') in the heart, kidneys and blood vessels, which are induced by a myocardial infarction or acute renal failure, for example Aldosterone the deposit of collagen proteins in the heart muscle, which can lead to increased stiffness and thus in the long term to a reduced functionality.

Another important control system is the cyclic guanosine monophosphate (cGMP) nitric oxide (NO) system. cGMP / O have a vasodilating effect and thus an antihypertensive effect. Certain enzymes, so-called guanylate cyclases, catalyze the biosynthesis of cGMP from guanosine triphosphate (GTP). The known members of this family can be divided into structural groups as well as the type of ligands in two groups: the particulate, by so-called natriuretic peptides stimulable guanylate cyclases (pGC) and the soluble, stimulable by NO guanylate cyclases (sGC). The particulate membranous guanylate cyclases consist of the cytosolic catalytic domain, a transmembrane region and the extracellular ligand-binding domain. The binding of natriuretic peptides to the extracellular ligand-binding domain leads to the activation of the catalytic domain and the biosynthesis of cGMP from GTP. The enzyme neprilysin inactivates natriuretic peptides by proteolytic cleavage and consequently has an inhibitory effect on the particulate guanylate cyclase. Natriuretic peptides such as e.g. the 'Atrial Natriuretic Peptide' (ANP), the is released from the atrium of the heart, act vasodilatory and lead in the kidney in a very short time to increased sodium excretion and thus renal aldosterone / mineralocorticoid receptor antagonists. In addition, they reduce the formation and / or release of renin, aldosterone and vasopressin. Thus, natriuretic peptides function functionally as antagonists of RAAS.

Aldosterone and angiotensin 11 form a classic, feed-forward 'regulatory circuit: in addition to potassium, angiotensin 11 is the main stimulus for the release of aldosterone from the adrenal glands, and conversely, aldosterone in heart tissue and vessels stimulates the production of ACE, the enzyme that precedes the precursor - angiotensin which generates angiotensin 11.

The pathophysiological effects of angiotensin I and aldosterone can be diminished by corresponding inhibitors of ACE, AT-R and MR, however, these singular blockages are subject to the above-mentioned. 'feed-back' compensation mechanisms, i. Blockade of the mineralocorticoid receptor results in compensatory release of aldosterone, similar to AT-R blockade leading to an increase in angiotensin II.

Long-term compensatory mechanisms play a special role in the clinically meaningful 'Aldosterone Escape' phenomenon: Since aldosterone release is, so to speak, the last step in the RAAS cascade, it was for a long time believed that the blockade of the initial RAAS key steps such as the ACE- Activity or the AT-Rs to prevent even the last step, aldosterone formation and release in the adrenal gland. However, the RESOLVD study (McKelvie et al., Circulation 1999; 100; 1056-1064) showed that both single ACE or AT-R blockade, as well as dual ACE AT-R blockade, aldosterone plasma levels in patients with heart failure, although it is reduced from baseline within the first 17 weeks of treatment, it even exceeds baseline levels after 43 weeks. The results of this study demonstrate that preventing the binding of aldosterone to the mineralocorticoid receptor in addition to angiotensin blockade is clinically important.

MR antagonists (such as the steroidal compounds spironolactone, canrenone / canrenoate and eplerenone, as well as newer non-steroidal MR antagonists such as MT-3995, CS-3150, LY2623091, PF-03882845 and finerenone (BAY 94-8862)), aldosterone-mediated sodium retention in the kidneys (natriuretic effect). Thus, MR antagonists lead to increased sodium excretion, which is a proven therapeutic concept in hypertensive patients and / or in patients with heart failure and / or renal insufficiency. However, MR antagonists can exert their natriuretic effect only in the kidney segments, in which aldosterone is also physiologically effective via MR. These are v. A. the late distal tubule and collection tube sections, which are involved in sodium reabsorption only to a limited extent, while the majority of sodium secretion and reabsorption in proximal tubule sections occurs.

LCZ696 is an AR! (Angiotensin receptor neprilysin inhibitor) and thus a dual agent consisting of the AT-R antagonist valsartan and the neprilysin inhibitor sacubitril. By the neprilysin inhibition one achieves a diminished degradation of natriuretic peptides. These act v.a. diuretic and natriuretic through its vasodilator effect on pre-glomerular vessels. In addition, they may also inhibit sodium reabsorption in proximal tubule sections.

The combination of AT-R blockade and neprilysin inhibition by LCZ696 (a combination of the AT-R antagonist valsartan and the NEP inhibitor sacubitril) has recently been evaluated in clinical trials (Phase III) in patients with heart failure and resulted in a reduction in death and hospitalization risks (McMurray et al 2014 NEJM). In addition to the desired increase in ANP and cGMP, compensatory increases in renin and angiotensin were measured with LCZ696 both in healthy volunteers and in hypertensive patients. Concerning. however, additional compensatory, feed-back or feed-forward regulations would require long-term data.

The invention provides a combination preparation containing finerenones with N- (3-carboxy-1-oxopropyl) -

(4S) - (p-phenylphenylmethyl) -4-amino-2R-methylbutanoic acid or an ester of the N- (3-carboxy-1-oxopropyl) - (4S) - (p-phenylphenyl-methyl) -4- amino-2R-methylbutanoic acid combined. The combination preparation shows acute and especially chronic use, positive effects on sodium excretion, end-organ protection of the heart and kidneys and reduction of morbidity and morality under experimental conditions. These experimental conditions consist on the one hand of healthy animals or animals with hypertension, cardiac and / or renal insufficiency (eg transgenic renin rats).

Simultaneous blockade of aldosterone binding to MR and blockade of neprilysm by the combination preparation of the invention result in over-additive effects on sodium excretion, end organ protection, and reduction of morbidity and mortality.

Here we claim the use of the non-steroidal MR antagonist Finerenone in combination with N- (3-carboxy-1-oxopropyl) - (4S) - (p-phenylphenyl-methyl) -4-amino-2R-methylbutanoic acid or an ester of of N- (3-carboxy-1-oxopropyl) - (4S) - (p-phenylphenyl-methyl) -4-amino-2R-methylbutanoic acid for the treatment of cardiovascular diseases such as Cardiac insufficiency with retained fraction or congestive heart failure with reduced fraction of ejaculation, treatment and / or prophylaxis of atrial fibrillation, stroke or atherosclerosis, renal diseases, e.g. chronic renal failure or diabetic nephropathy, pulmonary diseases, diseases of the central nervous system, for the treatment and / or prophylaxis of fibrotic diseases and other manifestations of disease (e.g., end-organ damage affecting the brain, kidney or heart).

An object of the present invention is a combination preparation comprising the mineralocorticoid receptor selective antagonist Finerenone and the NEP inhibitor N- (3).

Carboxy-1-oxopropyl) - (4S) - (p-phenylphenylmethyl) -4-amino-2R-methylbutanoic acid or an ester thereof, as well as the salts, solvates and solvates of the salts of Finerenone.

Finerenone is the non-steroidal mineralocorticoid receptor selective antagonist (5) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine 3-carboxamide of the formula (I)

Formula (I)

or a salt, solvate or solvate of the salts thereof and is described in DE 10 2007009494 Al and WO 2008 104 306 A2.

The NEP inhibitor of the present invention is N- (3-carboxy-1-oxopropyl) - (4S) - (p-phenylphenylmethyl) -4-amino-2R-methylbutanoic acid or an ester of the acid, or each salt, solvate or Solvate of salts of acid or ester. Acid and esters of the NEP inhibitor of the invention are described in EP 0 555 175 A1. A preferred form of N- (3-carboxy-1-oxopropyl) - (4S) - (p-phenylphenylmethyl) -4-amino-2R-methylbutanoic acid is the ethyl ester, N- (3-carboxy-1-oxopropyl) - ( 4S) - (p-phenylphenylmethyl) -4-amino-2R-methylbutanoic acid ethyl ester of the formula (II).

Formula (II)

With respect to ethyl N- (3-carboxy-l-oxopropyl) - (4S) - (p-phenylphenylmethyl) -4-amino-2R-methylbutanoate, preferred salts include the sodium salt, the triethanolamine salt and the tris (hydroxymethyl) aminomethane salt.

The components to be combined may be present as salts. Salts which are preferred in the context of the present invention are physiologically acceptable salts of the compounds to be combined. Also included are salts which are not suitable for pharmaceutical applications, but which can be used, for example, for the isolation or purification of the compounds to be combined.

The molar ratio of finerenone to NEP inhibitor of the invention in the combination preparation according to the invention is for example 0.01-10: 1, preferably 0.05-5: 1 and most preferred is a molar ratio of 0.1-1: 1.

The combination preparation according to the invention is suitable for the prophylaxis and / or treatment of various diseases and disease-related conditions, in particular for the treatment and / or prophylaxis of cardiovascular diseases, such as, for example, Cardiac insufficiency with retained fraction or congestive heart failure with reduced fraction of ejaculation, treatment and / or prophylaxis of atrial fibrillation, stroke or atherosclerosis, renal diseases, e.g. chronic renal failure or diabetic nephropathy, pulmonary diseases, central nervous system disorders, for the treatment and / or prophylaxis of fibrotic disorders, as well as other manifestations of disease (e.g., end-organ damage affecting the brain, kidney, or heart).

Furthermore, the combined preparation according to the invention is suitable for the prophylaxis and / or treatment of various diseases and disease-related conditions, in particular for the treatment and / or prophylaxis of a disease selected from the group consisting of hypertension, heart failure (acute and chronic), decompensated heart failure, left ventricular dysfunction, hypertrophic cardiomyopathy, diabetic cardiomyopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, harmful vascular remodeling, myocardial infarction and sequelae thereof, atherosclerosis, angina (unstable or stable), renal insufficiency (diabetic and nondiabetic), heart failure, angina pectoris, diabetes, secondary Hyperaldosteronism, primary and secondary pulmonary hypertension, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria secondary to renal disease, renal vascular hypertension, diabetic and non-diabetic retinopathy, migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction, glaucoma and stroke.

Another object of the present invention is the use of the combination preparation of the invention for the manufacture of a medicament for the treatment and / or prevention of diseases, in particular the aforementioned diseases.

Another object of the present invention is a method for the treatment and / or prevention of diseases, in particular the aforementioned diseases.

The combination preparation according to the invention can be used alone or as needed in combination with other active ingredients. Another object of the present invention are pharmaceutical compositions containing the inventive combination preparation and one or more other active ingredients, in particular for the treatment and / or prevention of the aforementioned diseases. As suitable combination active ingredients may be mentioned by way of example and preferably:

Hypotensive agents, by way of example and preferably from the group of calcium antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor B-relaxers, beta-receptor B-relaxers and rho-kinase inhibitors;

• Diuretics, especially loop diuretics and thiazides and thiazide-like diuretics;

Antithrombotic agents, by way of example and preferably from the group of platelet aggregation inhibitors, anticoagulants or profibrinolytic substances;

• fat metabolism-altering agents, by way of example and preferably from the group of thyroid receptor agonists, cholesterol synthesis inhibitors such as by way of example and preferably HMG-CoA reductase or S qualensynthese inhibitors, the ACAT inhibitors, CETP inhibitors, MTP inhibitors , PPAR-alpha, PPAR-gamma and / or PPAR-delta agonists, cholesterol-absorption inhibitors, lipase inhibitors, polymeric bile acid adsorber, bile acid

Reabsorption inhibitors and lipoprotein (a) antagonists;

Organic nitrates and NO donors, such as sodium nitroprusside, nitroglycerine, isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1, and inhaled NO; positive inotropic compounds such as cardiac glycosides (digoxin), beta adrenergic and dopaminergic agonists such as isoproterenol, epinephrine, norepinephrine, dopamine and dobutamine;

Compounds which inhibit the degradation of cyclic guanosine monophosphate (cGMP) and / or cyclic adenosine monophosphate (cAMP), such as inhibitors of phosphodiesterases (PDE) 1, 2, 3, 4 and / or 5, in particular PDE 5 inhibitors such as sildenafil, vardenafil and tadalafil, as well as PDE 3 inhibitors such as amrinone and milrinone;

natriuretic peptides, e.g. atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP, Nesiritide), C-type natriuretic peptide (CNP) and urodilatin;

Calcium sensitizers, such as by way of example and preferably levosimendan;

If-channel B loosely as exemplified and preferably ivabradine;

Myosin activators, by way of example and preferably Omecamtiv mecarbil;

NO-independent, but heme-dependent guanylate cyclase stimulators and / or NO and heme-independent activators of guanylate cyclase, in particular those described in WO03 / 097063, WO03 / 09545, WO04 / 009589, WO03 / 004503, WO02 / 070462, WO2007 / 045366, WO2007 / 045369, WO2007 / 045370, WO2007 / 045433, WO2007 / 045367, WO2007 / 124854, WO2007 / 128454, WO2008 / 031513, WO2008 / 061657, WO2008 / 119457, WO2008 / 119458, WO2009 / 127338, WO2010 / 079120, WO2010 / 102717, WO2011 / 051165, WO2011 / 147809, WO2011 / 141409, WO2014 / 012935, WO2012 / 059549, WO2012 / 004259, WO2012 / 004258, WO2012 / 059548, WO2012 / 028647, WO2012 / 152630, WO 2012/076466, WO2014 / 068099, WO2014 / 068104, WO2012 / 143510, WO2012 / 139888, WO2012 / 152629, WO2013 / 004785, WO2013 / 104598, WO2013 / 104597, WO2013 / 030288, WO2013 / 104703, WO2013 / 131923, WO2013 / 174736, WO2014 / 012934 WO2014 / 068095, WO2014 / 195333, WO2014 / 128109, WO2014 / 131760, WO2014 / 131741, WO2015 / 018808, WO2015 / 004105, WO2015 / 018814, WO98 / 16223, WO98 / 16507, WO98 / 23619, WO00 / 06569, WO01 / 19776, WO 01/19780, WO 01/1997 78, WO02 / 042299, WO02 / 092596, WO02 / 042300, WO02 / 042301, WO02 / 036120, WO02 / 042302, WO02 / 070459, WO02 / 070460, WO02 / 070461, WO02 / 070510, WO2012 / 165399, WO2014 / 084312, WO2011115804, WO2012003405, WO2012064559, WO2014 / 047111, WO2014 / 047325, WO2011 / 149921, WO2010 / 065275, WO2011 / 119518, WO2015 / 08885, WO2015 / 08886, WO2014 / 144100 and particularly preferred:

2- [i- (2-fluorobenzyl) -1H-pyrazolo [3,4-b] pyridino-3-yl] -5- (4-morpholinyl) -4,6-pyrimidinediamine disclosed as Example 16 in WO 00 / 06569,

2- [1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b] pyridin-3-yl] -5- (4-pyridinyl) -4-pyrimidine amine, disclosed as Example 1 in WO 02/42301,

Methyl-4,6-diamino-2- [l- (2-fluorobenzyl) -lH-pyrazolo [3,4-b] ^

(methyl) carbamate, disclosed as Example 8 in WO 03/095451,

Methyl-4,6-diamino-2- [i- (2-fluorobenzyl) -lH-pyrazolo [3,4-b] pyridin-3-yl] -5-pyrim

carbamate, disclosed as Example 5 in WO 03/095451

4 - ({(4-carboxybutyl) [2- (2 - {[4- (2-phenylethyl) benzyl] oxy} phenyl) ethyl] amino} methyl) carboxylic acid, disclosed as Example 8a in WO 01/019780,

Methyl {4,6-diamino-2- [5-fluoro-1- (2-fluorobenzyl) -1H-pyrazolo [3,4- b] pyridin-3-yl] pyrimidin-5-yl} carbamate, methyl {4,6-diamino-2- [5-fluoro-1- (2-fluorobenzyl) -1H-pyrazolo [3,4- b] pyridine-3-yl] pyrimidin-5-yl} methylcarbamate, methyl {4 , 6-diamino-2- [5-fluoro-1 - (2-fluorobenzyl) -1H-pyrazolo [3,4- b] pyridin-3-yl] pyrimidin-5-yl} (2,2,2-) trifluoroethyl) carbarnate, disclosed in WO 2011/147809, 5-chloro-2- (5-chlorothiophene-2-sulfonylanilino-N- (4- (mono-holine-4-sulfonyl) -phenyl) -benzamide as the sodium salt, disclosed in WO00 / 02851,

2- (4-Chlorophenylsulfonylamino) -4,5-dimethoxy-N- (4- (thiomholin-4-sulfonyl) -phenyl) -benzamide disclosed in WO00 / 02851,

1- {6- [5-chloro-2 - ({4-trans-4-trifluoromethyl) cyclohexyl] benzyl} oxy) phenyl] pyridin-2-yl} -5- (trifluoromethyl) -1H-pyrazole-4 carboxylic acid disclosed in WO 2009/032249,

1- [6- (2- (2-Methyl-4- (4-trifluoromethoxyphenyl) benzyloxy) -phenyl) pyridin-2-yl] -5-trifluoromethyl-pyrazole-4-carboxylic acid disclosed in WO 2009/071504,

1- [6- (3,4-Dichlorophenyl) -2-pyridinyl-5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid disclosed in US-A-5,648,347

WO 2009/068652,

1 - ({2 - [3-Chloro-5 - (trifluoromethyl) -phenyl] -5-methyl-1, 3-thiazol-4-yl} -methyl) -1 H -pyra-ol-4-carboxylic acid, 4- ( {2- [3- (trifluoromethyl) phenyl] -1,3-thiazol-4-yl} methyl) benzoic acid and 1- ({2- [2-fluoro-3- (trifluoromethyl) phenyl] -5-methyl-1 , 3-thiazol-4-yl} methyl) -1H-pyrazole-4-carboxylic acid disclosed in WO 2009/123316,

4-Amino-2- [5-chloro-3 (3,3,3-trifluoro-ropyl) -iH-indazolyl] -5,5-dimethyl-5,7-dihydro-6H-pyrrolo [2,3- d] pyrimidin-6-one, 4-amino-2 [5-chloro-3- (2,3,6-trifluorobenzyl) -1H-indazolyl] -5,5-dimethyl-5,7-dihydro-6H -pyrrolo [2,3-d] pyrimidin-6-one, 4-amino-5,5-dimethyl-2- [3- (2,3,6-trifluorobenzyl) -1H-thieno [3,4-c] pyrazole -l-yl] -5,7-dihydro-6H-pyrrolo [2,3-d] pyrimidin-6-one, 4-amino-5,5-dimethyl-2- [3- (2,3,6-) trifluorobenzyl) -1H-thieno [2,3-d] pyrazol-1-yl] -5,5-dimethyl-5,7-dihydro-6H-pyrrolo [2,3-d] pyrimidin-6-one, 4- Amino-5,5-dimethyl-2- [7- (2,3,6-trifluorobenzyl) imidazo [l, 5-b] pyridazin-5-yl] -5,7-dihydro-6H-pyrrolo [2,3 -d] pyrimidin-6-one, 4-amino-2- [6-chloro-3- (2,3,6-trifluorobenzyl) imidazo [i, 5-a] pyridin-1-yl]] - 5,5 -dimethyl-5,7-dihydro-6H-pyrrolo [2,3-d] pyrimidin-6-one, 4-amino-2- [6-fluoro-3- (2,3,6-) Trifluorobenzyl) imidazo [l, 5-a] pyridin-l-yl]] - 5,5-dm

d] pyrimidin-6-one, 4-amino-2- [6-fluoro-3- (2,3,6-trifluorobenzyl) -6-fluoroimidazo [l, 5-a] pyridin-1-yl] -5,5 -dimethyl-5,7-dihydro-6H-pyrrolo [2,3-d] pyrirnidin-6-one, 4-amino-5,5-dimethyl-2- [3- (2,4,6-trifluorobenzyl) imidazo [l, 5-a] pyridin ^

4-Amino-2- [3- (2-cyclopentylethyl) imidazo [l, 5-a] pyridm ^

pyrrolo [2,3-d] pyrimidin-6-one, disclosed in WO 2010/065275,

3- (4-Amino-5-cyclopropylpyrimidin-2-yl) -i- (2-fluorobenzyl) -l / -pyrazolo [3,4- ''] pyridines known as BAY 41-2272 disclosed as Example 1 in WO 00 / 06568,

2- {5-Fluoro-l - [(3-fluoropyridin-2-yl) -methyl] -1H-pyrazolo [3,4-b] pyridin-3-yl} -5-niethyl-5- (trifluoromethyl) -4 - [(3,3,3-trifluoroproyl) amino] -5,7-dihydro-6H-pyrrolo [2,3

disclosed as Example 1 in WO 2014/131760

3- (4-chloro-3 - {[(2S, 3R) -2- (4-chlorophenyl) -4,4,4-trifluoro-3-methylbutanoyl] amino} phenyl 1) -3-cyclopropylpropanoic acid disclosed as Example 22 in WO 2012/139888.

Human neutrophil elastase inhibitors (HNE), such as Sivelestat or DX-890 (Reltran);

The signal transduction cascade inhibiting compounds, such as tyrosine kinase inhibitors, especially sorafenib, imatinib, gefitinib and erlotinib; and or

• the energy metabolism of the heart affecting compounds, such as by way of example and preferably etomoxir, dichloroacetate, ranolazines or trimetazidines.

In a preferred embodiment of the invention, the combination preparation according to the invention is used in combination with a diuretic, such as by way of example and preferably furosemide, bumetanide, torsemide, bendroflumethiazide, chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methylcidothiazide, polythiazide, trichloromethiazide, chlorthalidone, indapamide, metolazone , Quinethazone, acetazolamide, dichlorophenamide, methazolamide, glycerol, isosorbide, mannitol, amiloride or triamterene.

Among the antihypertensive agents are preferably compounds from the group of calcium antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor B-relaxer, beta-receptor B-lover, Rho-kinase inhibitors and diuretics Understood.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered in combination with a calcium antagonist, such as, by way of example and by way of preference, nifedipine, amlodipine, verapamil or diltiazem.

In a preferred embodiment of the invention, the combination preparation according to the invention is used in combination with an ACE inhibitor, by way of example and by way of example Enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered in combination with an endothelin antagonist, such as, for example and preferably, bosentan, darusentan, ambrisentan or sitaxsentan.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered in combination with a renin inhibitor such as, for example and preferably, aliskiren, SPP-600, SPP-635, SPP-676, SPP-800 or SPP-1148.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered in combination with an alpha-1-receptor blocker, such as by way of example and preferably prazosin.

In a preferred embodiment of the invention, the combination preparation according to the invention is used in combination with a beta-receptor blocker such as, for example and preferably, propranolol, atenolol, timolol, pindolol, alprenolol, oxprenolol, penbutolol, bupranolol, metipranolol, nadolol, mepindolol, carazalol , Sotalol, metoprolol, betaxolol, celiprolol, bisoprolol, carteolol, esmolol, labetalol, carvedilol, adaprolol, landiolol, nebivolol, epanolol or bucindolol.

In a preferred embodiment of the invention, the combination preparation according to the invention is used in combination with a rho-kinase inhibitor such as, for example and preferably, Fasudil, Y-27632, SLx-2119, BF-66851, BF-66852, BF-66853, KI -23095 or BA-1049.

Antithrombotic agents (antithrombotics) are preferably understood as meaning compositions from the group of platelet aggregation inhibitors, anticoagulants or profibrinolytic substances.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered in combination with a platelet aggregation inhibitor such as, for example and preferably, aspirin, clopidogrel, ticlopidine or dipyridamole.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered in combination with a thrombin inhibitor, such as by way of example and preferably ximelagatran, melagatran, bivalirudin or Clexane.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered in combination with a GPIIb / IIIa antagonist, such as, by way of example and by way of preference, tirofiban or abciximab. In a preferred embodiment of the invention, the combination preparation according to the invention is used in combination with a factor Xa inhibitor, such as by way of example and preferably rivaroxaban (BAY 59-7939), DU-176b, apixaban, otamixaban, fidexaban, razaxaban, fondaparinux, idraparinux, PMD-3112, YM-150, KFA-1982, EMD-503982, MCM-17, MLN-1021, DX 9065a, DPC 906, JTV 803, SSR-126512 or SSR-128428.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered in combination with heparin or a low molecular weight (LMW) heparin derivative.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered in combination with a vitamin K antagonist, such as by way of example and preferably coumarin.

Among the lipid metabolizing agents are preferably compounds from the group of CETP inhibitors, thyroid receptor agonists, cholesterol synthesis inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors, the ACAT inhibitors, MTP inhibitors, PPAR-alpha. PPAR gamma and / or PPAR delta agonists, cholesterol absorption inhibitors, polymeric bile acid adsorbers, bile acid reabsorption inhibitors, lipase inhibitors and the lipoprotein (a) antagonists understood.

In a preferred embodiment of the invention, the combination preparation according to the invention is admixed with a CETP inhibitor such as, for example and preferably, torcetrapib (CP-529 414), JJT-705, BAY 60-5521, BAY 78-7499 or CETP-vaccine (Avant). administered.

In a preferred embodiment of the invention, the combination preparation according to the invention is used in combination with a thyroid receptor agonist, such as by way of example and preferably D-thyroxine, 3, 5, 3'-triiodothyronine (T3), CGS 23425 or axitirome (CGS 26214), administered.

In a preferred embodiment of the invention, the combination preparation according to the invention is combined with an HMG-CoA reductase inhibitor from the class of statins such as, for example and preferably, lovastatin, simvastatin, pravasatin, fluvastatin, atorvastatin, rosuvastatin, cerivastatin or pitavastatin administered.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered in combination with a squalene synthesis inhibitor, such as by way of example and preferably BMS-188494 or TAK-475.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered in combination with an ACAT inhibitor such as, for example and preferably, avasimibe, melinamide, pactimibe, eflucimibe or SMP-797. In a preferred embodiment of the invention, the combination preparation according to the invention is used in combination with an MTP inhibitor, such as by way of example and preferably implitapide, BMS-201038, R! 03757 or JTT-130. Administered.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered in combination with a PPAR-gamma agonist, such as by way of example and preferably pioglitazone or rosiglitazone.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered with a PPAR-delta agonist such as, for example and preferably, GW-501516 or BAY 68-5042.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered with a cholesterol absorption inhibitor, such as, for example and preferably, ezetimibe, tiqueside or pamaqueside.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered with a lipase inhibitor, such as, by way of example and by way of preference, quistlate.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered in combination with a polymeric bile acid adsorbent, such as, for example and preferably, cholestyramine, colestipol, colesolvam, cholesta gel or colestimide.

In a preferred embodiment of the invention, the combination preparation according to the invention is used in combination with a bile acid reab tion inhibitor, such as by way of example and preferably AS BT (= IB AT) inhibitors such as e.g. AZD-7806, S-8921, AK-105, BARI-1741, SC-435 or SC -635.

In a preferred embodiment of the invention, the combination preparation according to the invention is administered in combination with a lipoprotein (a) antagonist, such as, for example and preferably, gemcabene calcium (CT 1027) or nicotinic acid.

The compounds according to the invention can act systemically and / or locally. For this purpose, they may be applied in a suitable manner, e.g. oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival, otic or as an implant or stent.

For these administration routes, the compounds according to the invention can be administered in suitable administration forms.

For the oral administration are according to the prior art functioning, the compounds of the invention rapidly and / or modified donating application forms, the compounds of the invention in crystalline and / or amorphized and / or dissolved form such as tablets (uncoated or coated tablets, for example with enteric or delayed-dissolving or insoluble coatings which control the release of the compound of the invention), orally disintegrating tablets or films / wafers, films / lyophilisates, capsules ( hard or soft gelatin capsules, for example), dragees, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.

Preferred forms of administration are tablet form (uncoated or coated tablets, for example with enteric or delayed-dissolving or insoluble coatings, which control the release of the compound according to the invention), tablets rapidly disintegrating in the oral cavity or films / wafers.

Parenteral administration can be accomplished by bypassing a resorption step (e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar) or by resorting to absorption (e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally). For parenteral administration are suitable as application forms u.a. Injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.

For the other routes of administration are suitable, for example Inhalant medicines (including powder inhalers, nebulizers), nasal drops, solutions or sprays, lingual, sublingual or buccal tablets, films / wafers or capsules, suppositories, ear or ophthalmic preparations, vaginal capsules, aqueous suspensions (lotions, shaking mixtures) lipophilic suspensions, ointments, creams, transdermal therapeutic systems (eg patches), milk, pastes, foams, powdered powders, implants or stents.

Preferred are oral or parenteral administration, with oral administration being more preferred. Especially preferred is oral administration by means of tablet form.

The compounds of the invention can be converted into the mentioned application forms. This can be done in a conventional manner by mixing with inert, non-toxic, pharmaceutically suitable excipients. These adjuvants include, among others. Carrier materials (for example microcrystalline cellulose, lactose, mannitol), solvents (for example liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example sodium dodecyl sulfate, polyoxysorbitanoleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers (for example albumin), stabilizers (for example antioxidants such as ascorbic acid), dyes (eg, inorganic pigments such as iron oxides), and flavor and / or odor remedies.

In the combination preparation according to the invention, the components may be used together or sequentially or separately in a combined dosage form or in two separate Unit dosage forms are administered. The unit dosage form may also be a fixed combination.

A therapeutically effective amount of each component of the combination of the invention may be administered simultaneously or sequentially in any order.

In one embodiment, the components may be in a so-called sustained-release formulation in which the release of the components according to the invention takes place at different times. For example, mention may be made of a tablet having delayed-dissolving coatings, each containing one or more of the components according to the invention.

In the event that the components of the combination of the invention are administered in separate unit dosage forms, for example, finerenone and NEP inhibitor may be provided as a capsule or tablet, respectively.

When administered orally, the dosage of finerenone is about 1 to 100 mg od, preferably about 2.5 to 50 mg od and most preferably 10 to 20 mg od.

Especially preferred are dosages of finerenone on oral administration of 1.25 mg od, 2.5 mg od, 5 mg od, 7.5 mg od, 15 mg od or 20 mg od.

The dosage of the NEP inhibitor is about 1 to 1000 mg bid, preferably about 10 to 500 mg bid and most preferably 24 to 97 mg bid.

In a preferred embodiment of the invention, the dosage of Finerenone is about 1 to 100 mg od and the dosage of NEP inhibitor is about 1 to 1000 mg bid, preferably the dosage of Finerenone is about 2.5 to 50 mg od and the dosage of NEP Inhibitors about 10 to 500 mg bid and most preferably the dosage of finerenone is about 10-20 mg od and the dosage of the NEP inhibitor about 24 to 97 mg bid.

Nevertheless, it may be necessary to deviate from the stated amounts, depending on body weight, route of administration, individual behavior towards the active ingredient, type of preparation and time or interval at which the application is carried out. Thus, in some cases it may be sufficient to manage with less than the aforementioned minimum amount, while in other cases, the said upper limit must be exceeded. In the case of the application of larger quantities, it may be advisable to distribute these in several single doses throughout the day.

The invention also relates to the combination of separate pharmaceutical compositions in kit form. This is a kit comprising two separate entities: a pharmaceutical Finerenone composition and a pharmaceutical NEP inhibitor composition. The invention also relates to a preferred kit form comprising two units: A pharmaceutical composition comprising finerenones and NEP inhibitor and a pharmaceutical composition comprising NEP inhibitor.

The kit is particularly advantageous when the separate components must be administered in different dosage forms or administered at different dose intervals.

Exemplary embodiments of pharmaceutical compositions

The compounds according to the invention can be converted into pharmaceutical preparations as follows:

Tablet:

Finerenone Composition 1:

100 mg finerenone, 50 mg lactose (monohydrate), 50 mg corn starch (native), 10 mg polyvinyl pyrrolidone (PVP 25) (BASF, Ludwigshafen, Germany) and 2 mg magnesium stearate.

Tablet weight 212 mg. Diameter 8 mm, radius of curvature 12 mm.

production:

The mixture of compound of the invention, lactose and starch is granulated with a 5% solution (m / m) of the PVP in water. The granules are mixed after drying with the magnesium stearate for 5 minutes. This mixture is compressed with a conventional tablet press (for the tablet format see above). As a guideline for the compression, a pressing force of 15 kN is used.

Kapseini

1000 capsules each with 50 mg active ingredient

Ethyl N- (3-carboxy-1-oxopropyl) - (4S) - (p-phenvl-phen-4-methyl-4-amino-2R-methvlbutanoate) Composition:

50 g of ethyl N- (3-carboxy-l-oxopropyl) - (4S) - (p-phenylphenylmethyl) -4-amino-2R-methylbutanoate sodium salt, 187 g of lactose, 80 g of modified starch and 3 g of magnesium stearate.

production:

All powders are sieved through a sieve with sieve openings of 0.6 mm. The active ingredient is placed in a suitable mixer and then mixed first with magnesium stearate and later with lactose and starch until a homogeneous mixture is obtained. Hard gelatin capsules are each filled with 300 mg of the mixture. Finerenone Composition 2:

A granulated solution Finerenone in crystalline form and micronized form, Hypromellose 5 cP, Natriumlaurilsufat was prepared in purified water.

Cellulose microcrystalline, lactose monohydrate and croscarmellose sodium were mixed in a container or a fluidized bed granulator (premix).

The premix and the granule solution were granulated in the fluid-bed granulator.

The Lubricant Magnesium Stearate was added after the granules were dried and sieved. Thus, a press-ready mixture was prepared.

Using a rotary tablet press, the press-ready mixture was pressed into tablets.

A homogeneous coating suspension was made from hypromellose, talc, titanium dioxide, yellow iron oxide, red iron oxide and purified water. In a suitable coating device, the coating suspension was sprayed onto the tablets.

Composition Ph I Ib Ph I Ib Ph IIb Ph I Ib Ph I Ib Ph I Ib Ph I Ib

[mg] [mg] [mg] [mg] [mg] [mg] [mg]

Finerenone 1.25 2.50 5.00 7.50 10.00 15.00 20.00

Excipients

cellulose

73.80 72.50 69.90 67.30 64.70 62.00 59.30 microcrystalline

croscarmellose

4.50 4.50 4.50 4.50 4.50 4.50 4.50 sodium

Hypromellose 5 P 4.50 4.50 4.50 4.50 4.50 4.50 4.50

lactose

45.00 45.00 45.00 45.00 45.00 42.50 40.00 monohydrate

Magnesium stearate 0.90 0.90 0.90 0.90 0.90 0.90 0.90

Sodium lauryl sulphate 0.05 0.10 0.20 0.30 0.40 0.60 0.80

Weight

(uncoated 130.00 130.00 130.00 130.00 130.00 130.00 130.00

Tablet)

Film-coating

Hypromellose 5 cP 3.0336 3.0336 3.0336 3.0336 3.0336 3.0336 3.0336

Titanium dioxide 2.3196 2.3196 2.3196 2.3196 2.3196 2.3196 2.3196

Talcum 0.6072 0.6072 0.6072 0.6072 0.6072 0.6072 0.6072

Iron oxide yellow 0.0324 0.0324 0.0324 0.0324 0.0324 0.0324 0.0324 Red iron oxide 0.0072 0.0072 0.0072 0.0072 0.0072 0.0072 0.0072 Weight (film- 6.000Ü 6.0000 6.0000 6.0000 6.0000 6.0000 6.0000 coatin «)

Weight

(coated 136.00 136.00 136.00 136.00 136.00 136.00 136.00

Tablet)

Evaluation of physiological activity

The suitability of the compounds according to the invention for the treatment of cardiovascular diseases can be demonstrated in the following assay systems:

1.) In vivo test for the detection of natriuretic activity in conscious rats in metabolic cages

Wistar rats (250-350 g body weight) are kept with free access to feed (Altromin) and drinking water. Starting approx. 72 hours before the start of the experiment, instead of the normal diet, the animals are given only salt-reduced food with a content of 0.02% sodium chloride (ssniff R / MH, 10 mm with 0.02% Na, S0602-E081, ssniff Spezialdiäten GmbH). D-59494 Soest). During the experiment, the animals are kept individually for approximately 24 hours in metabolic cages suitable for rats of this weight class (Tecniplast Deutschland GmbH, D-823 3 Hohenpeissenberg) with free access to salt-reduced food and drinking water. At the beginning of the test, the substance to be tested is administered to the animals in a volume of 0.5 ml / kg body weight of a suitable solvent in the stomach by means of a gavage. Control animals receive only solvents. Controls and substance testing are done in parallel on the same day. Control groups and substance dose groups each consist of 6 to 8 animals. During the experiment, the urine excreted by the animals is continuously collected in a container on the floor of the cage. For each animal, the urine volume per unit of time is determined separately and the concentration of the sodium or potassium ions excreted in the urine is measured by standard flame photometric methods. The measuring intervals are typically the period up to 8 hours after the start of the test (day interval) and the period from 8 to 24 hours after the start of the test (night interval).

2.) Chronic myocardial infarction model in the rat

Male Wistar Han rats (Charles River, 280-300g) are anesthetized with Rompun 2% and Ketavet 1: 5, inhibited, connected to a ventilation pump (ugo basile 7025 rodent, 50 strokes per minute, 7 ml) and compressed air / oxygen mixture 1 : 2 ventilated. The body temperature is maintained at 37-38 ° C by a heat mat. As analgesic 0.05 mg / kg lml / kg (1:10) given subcutaneously temgesic. The thorax is opened laterally between the third and fourth ribs and the heart is exposed. The coronary artery of the left ventricle (LAD) is punctured with a occlusion thread (PROLENE 1 metric 5-0 ETHICON1H) just below its origin (below the left atrium) and permanently ligated. The occurrence of myocardial infarction is monitored by an ECG measurement (AD Instruments Power Lab 8/30). The lungs are inflated by briefly disconnecting the exhalation tube. The thorax is closed again and the muscle layers are sutured with ETHIBOND excel 1 metric 5/0 6951H and the epidermis with ETHIBOND excel 3/0 65 Sil. The surgical suture is covered with silver powder (eg Fissan) and then the anesthesia is terminated. As a further control, a "sham" group, in which only the surgical procedure but not the LA D occlusion was carried out, was taken 24 hours after the infarction, and retroorbital blood (Li Hep plasma) was taken for the troponin determination.

The animals were randomized at surgery and divided into individual treatment groups as well as into a control group without substance treatment. The substance treatment takes place once or twice daily for 8 weeks p.o. 2ml / kg (the first treatment is 24h after surgery), or by adding the test substances in the feed or drinking water.

Eight weeks after occlusion, the animals are again anesthetized (2% isoflurane) and a pressure catheter (Miliar SPR-320 2F) for 2 minutes in the carotid artery and then introduced for 2 minutes in the left ventricle. It records heart rate, left ventricular pressure (LVP), left ventricular end-diastolic pressure (L VII DP), contractility (dp / dt), and relaxation rate (tau) using the Powerlab system (AD Instruments, Power Lab 3/80) and the Chart7 software and evaluated. Subsequently, blood samples for analysis of certain parameters, e.g. BNP, angiotensin or aldosterone were removed and the animals were killed. Heart, lungs and kidney are removed and weighed. The tissue samples can be used for further histological examinations as well as for gene expression analyzes. 3.) DOCA / salt model

Administration of desoxycorticosterone acetate (DOCA) in combination with a high salt diet and unilateral renal clearance in the rat induces hypertension characterized by relatively low renin levels. As a result of this endocrine hypertension (DOCA is a direct precursor of aldosterone), depending on the DOCA concentration chosen, cardiac hypertrophy and other end organ damage, e.g. the kidney, the u.a. characterized by proteinuria and glomerulosclerosis. In this rat model, test substances can thus be tested for the presence of antihypertrophic and endorphin protective effects.

About 8 weeks old (body weight between 250 and 300 grams), male Sprague Dawley (SD) rats are left uninephrectomized. The rats are anaesthetized with 1.5-2% isoflurane in a mixture of 66% N2O and 33% O2 and the kidney is anesthetized Flank cut removed. As a later control animals serve so-called sham operated animals, which no kidney is removed.

Uninephrectomized SD rats receive 1% sodium chloride in drinking water and once weekly a subcutaneous injection of DOCA (company SIGMA, dissolved in sesame oil, high dose: 100 mg / kg / wk s.c., normal dose: 30 mg kg / wk s.c.) injected between the shoulder blades.

The substances to be tested for their protective effect in vivo are administered by gavage or by food (Ssniff, Germany). The animals are randomized one day before the start of the experiment and assigned to groups with the same number of animals, usually n = 10. Throughout the experiment, the animals have access to drinking water and food ad libitum. The substances are administered once a day for 4-12 weeks by gavage or by food. The placebo group used is animals that are treated in exactly the same way, but receive either only the solvent or the feed without the test substance.

Hemodynamic parameters (blood pressure, heart rate, inotropy [dp / dt], relaxation time [tau], maximal left ventricular pressure, left ventricular enddiastolic pressure [LVEDP]) are measured and the weights of heart, kidney and lung are determined, protein excretion and gene expression of Biomarkers (eg ANP, Atrial Natriuretic Peptides, and BNP, Brain Natriuretic Peptides, Angiotensin and Aldosterone) by RIA. ELISA or RT / TaqMan PCR after RNA isolation from cardiac and renal tissues.

4.) L-NAME Treated Renal Transgenic Rat (TGR (mRen2) 27)

The transgenic renin rat, TGR (mRen2) 27 'is a hypertensive rat line developed by Mullins and Ganten that overexpresses the mouse Ren-2 gene. Additional administration of the nitric oxide synthase inhibitor L-NAME induces endothelial dysfunction, which increases morbidity and mortality in this model. Homozygous animals die of secondary complications, such as heart and kidney failure, or stroke, unless they undergo lifelong, antihypertensive therapy.

Male TGR (mRen2) Twenty-seven renin rats aged 10 to 20 weeks are randomized to various pharmacological treatment groups and a placebo group. In addition, the nitric oxide synthase inhibitor, L-NAME, is administered via the drinking water at a concentration of 30 to 100 mg / l. Throughout the experiment, the animals have access to drinking water and food ad libitum. The substances are administered daily for 4-10 weeks by gavage or by food. The placebo group used is animals that are treated in exactly the same way, but receive either only the solvent or the feed without the test substance. During the trial, the determination of systolic blood pressure by S chwanzmans chette (tail cuff), as well as the determination of proteinuria and urine electrolyte composition by urine collection in metabolic cages, are carried out at regular intervals. At the end of the experiment Hemodynamic parameters (blood pressure, heart rate, inotropy [dp / dt], relaxation time [tau], maximal left ventricular pressure, left ventricular enddiastolic pressure [LVEDP]) are measured, weights of heart, kidney and lung are determined, protein excretion and biomarkers (eg ANP , RIA Kit RK 005-24, Phoenix Pharmaceuticals, Inc., USA, cGMP, RIA Kit RE29075, IBL International GmbH, Hamburg, Renin, Angiotensin I. RIA Kit CA-1533, DiaSorin SpA, Italy, and Aldosterone, P2714, DiaSorin SpA, Italy), as well as gene expression of biomarkers by RT / TaqMan PCR after RNA isolation from cardiac and renal tissue.

Claims

claims

1. Combination preparation comprising:

Finerenones and N- (3-carboxy-1-oxopropyl) - (4S) - (p-phenylphenyl-methyl) -4-amino-2R-methylbutanoic acid or the esters thereof, and in each case the salts, solvates and solvates of the salts of Finerenones and N- (3-carboxy-1-oxopropyl) - (4S) - (p-phenylphenyl-methyl) -4-amino-2R-methylbutanoic acid or the ester thereof.

2. The combination preparation according to claim 1 for the treatment and / or prophylaxis of diseases.

3. The combination preparation according to any one of claims 1 or 2 for use in a method for the treatment and / or prophylaxis of cardiovascular diseases, renal diseases, lung diseases, and for the treatment and / or prophylaxis of fibrotic diseases.

4. The combination preparation according to any one of claims 1 to 3, wherein the molar ratio of finerenone to N- (3-carboxy-1-oxopropyl) - (4S) - (p-phenylphenyl-methyl) -4-amino-2R- methylbutanoic acid or the esters thereof is 0.1-1: 1.

5. Use of a combination preparation according to claim 1 for the manufacture of a medicament for the treatment and / or prophylaxis of cardiovascular diseases, renal diseases, lung diseases, as well as for the treatment and / or prophylaxis of fibrotic diseases.

6. A pharmaceutical composition comprising a combination preparation according to any one of claims 1 to 5 in combination with an inert, non-toxic, pharmaceutically suitable excipient.

7. A medicament comprising a combination preparation according to any one of claims 1 to 5, in combination with one or more further active ingredients selected from the group consisting of ACE inhibitors, beta-blockers, acetylsalicylic acid, diuretics, Ir channel blocker (Ivabradine), calcium Antagonists, statins, digitalis (digoxin) derivatives, calcium sensitizers, nitrates and antithrombotics.

8. Medicament according to claim 6 or 7 for the treatment and / or prophylaxis of cardiovascular diseases, renal diseases, lung diseases, as well as for the treatment and / or prophylaxis of fibrotic diseases.

9. A method for the treatment and / or prophylaxis of cardiovascular diseases, renal diseases, lung diseases, and for the treatment and / or prophylaxis of fibrotic diseases in humans and animals using a combination preparation according to any one of claims 1 to 5, or a medicament according to one of claims 6 to 8. The combination preparation according to any one of claims 1 to 4 for the treatment and / or prophylaxis of diseases wherein Finerenone is administered once a day and N- (3-carboxy-1-oxopropyl) - (4S) - (p-phenylphenylmethyl) -4 amino-2R-methylbutanoic acid or ester thereof is administered twice a day.

The combination preparation according to any one of claims 1 to 4 and 10 for the treatment and / or prophylaxis of diseases, wherein 10 to 20 mg of finerenone and 24 to 97 mg of N- (3-carboxy-1-oxopropyl) - (4S) - (p -) phenylphenylmethy1) -4-amino-2R-methylbutanoic acid or the esters thereof.

A kit comprising a pharmaceutical composition comprising finerenones and N- (3-carboxy-1-oxopropyl) - (4S) - (p-phenylphenylmethyl) -4-amino-2R-methylbutanoic acid or the esters thereof and a pharmaceutical composition comprising N - (3-carboxy-1-oxopropyl) - (4S) - (p-phenylphenylmethyl) -4-amino-2R-methylbutanoic acid or the esters thereof.